News

Net profit of Strides Pharma Science rose 54.45% to Rs 126.94 crore in the quarter ended March 2026 as against Rs 82.19 crore during the previous quarter ended March 2025. Sales rose 11.18% to Rs 1323.47 crore in the quarter ended March 2026 as against Rs 1190.39 crore during the previous quarter ended March 2025.For the full year,net profit declined 84.52% to Rs 556.19 crore in the year ended March 2026 as against Rs 3593.46 crore during the previous year ended March 2025. Sales rose 6.43% to Rs 4858.68 crore in the year ended March 2026 as against Rs 4565.34 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales1323.471190.39 11 4858.684565.34 6 OPM %18.1118.30 -19.0417.58 - PBDT207.71182.66 14 897.93614.52 46 PBT154.46133.80 15 695.53422.26 65 NP126.9482.19 54 556.193593.46 -85 Powered by Capital Market - Live News

Strides Pharma Science announced that the Board of Directors of the Company at its meeting held on 18 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 18 May 2026.

Strides Pharma Science announced that Strides Pharma Inc. (SPI), a step-down wholly owned subsidiary of the Company in the USA, has received the USFDA Inspection Closure Report (Establishment Inspection Report - EIR) for its Formulations Facility located at Chestnut Ridge, New York, USA. The Facility was inspected by the United States Food and Drug Administration (USFDA) from 17 December 2025 to 23 December 2025. The inspection covered current Good Manufacturing Practices (cGMP) and included a pre-approval inspection for Drug-Device Combination capabilities, covering the Company`s recent filing in Nasal Sprays domain. Based on SPI`s response to the Form 483 that was issued at the conclusion of the inspection, the USFDA has classified the inspection outcome as VAI (Voluntary Ac on Indicated). The EIR states that the inspection has been closed. The Chestnut Ridge facility caters to the U.S. market and manufactures Liquids, Gels, Hormones, Modified Release products and Controlled Substances, supporting several current and future products for the U.S. market. The successful closure of this inspection including Device Combinations further strengthens the Company`s U.S. business and near term growth prospects.Powered by Capital Market - Live News

Net profit of Strides Pharma Science rose 129.80% to Rs 202.11 crore in the quarter ended December 2025 as against Rs 87.95 crore during the previous quarter ended December 2024. Sales rose 3.55% to Rs 1194.65 crore in the quarter ended December 2025 as against Rs 1153.67 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1194.651153.67 4 OPM %19.7518.23 - PBDT299.40164.70 82 PBT248.78116.28 114 NP202.1187.95 130 Powered by Capital Market - Live News